Siervo 2015 (Br J Nutr) is a systematic review and meta-analysis of 20 RCTs (1917 participants, intervention duration 2-24 weeks) of the DASH dietary pattern against a control diet, on blood pressure and metabolic risk factors. It is the wiki’s DASH-specific pooling — distinct from the whole-named-diet network of Named Diet Programs Compared (which ranks DASH against 13 other programmes on weight and cardiovascular risk factors, finding between-diet differences trivial) and from the single-electrolyte pages (Sodium Intake and Blood Pressure, Potassium Intake and Blood Pressure). (Siervo et al., 2014)
One caveat governs the whole page: every measured endpoint is a SURROGATE — blood pressure, lipids, glucose. No hard outcome (mortality, MI, stroke, incident CVD) is measured; the trials are 2-24 weeks long. The often-quoted ~13% reduction in 10-year CVD risk is a Framingham risk-score projection of the BP + cholesterol changes (a computed score, not an observed event count) -> Surrogate Outcomes. What DASH does to events is a separate, not-established-here claim (transmission held on Blood Pressure Lowering and Cardiovascular Events).
A number-decoding note. The source PDF’s OCR renders minus signs as a leading
2andP<asP,(e.g. it prints the SBP effect as25·2 mmHg ... P,0·001). Every effect below is the decoded value (-5.2 mmHg,P<0.001), read against the sign-consistent abstract, results and forest plots. Quoted prose spans are OCR-clean and reproduce verbatim; the garbled numeric strings are deliberately NOT quoted verbatim.
The pooled effects — BP and atherogenic lipids move, glucose/HDL/TAG do not
DASH vs control, random-effects pooled mean differences (Siervo et al., 2014):
| Risk factor | DASH vs control (95% CI) | P | State |
|---|---|---|---|
| Systolic BP | -5.2 mmHg (-7.0, -3.4) | <0.001 | benefit (I2=76%, high heterogeneity) |
| Diastolic BP | -2.6 mmHg (-3.5, -1.7) | <0.001 | benefit |
| Total cholesterol | -0.20 mmol/l (-0.31, -0.10) | <0.001 | benefit |
| LDL cholesterol | -0.10 mmol/l (-0.20, -0.01) | 0.03 | benefit (small) |
| Glucose | -0.19 mmol/l | 0.07 | no meaningful effect |
| HDL cholesterol | +0.003 mmol/l (-0.05, 0.05) | 0.95 | no meaningful effect |
| Triglycerides | -0.005 mmol/l (-0.06, 0.05) | 0.87 | no meaningful effect (Egger P=0.01, some publication bias) |
The BP effect was robust to study design (controlled-feeding vs dietary-advice) and control-diet type, though the SBP decline was larger against a typical American control than against an already-healthy control diet. (Siervo et al., 2014)
Effect modification — larger BP fall at higher baseline BP and higher BMI (route-b)
«Reductions in systolic and diastolic BP following randomisation to the DASH diet were greater in participants with higher BP or BMI at baseline. For each mmHg increase in baseline systolic and diastolic BP, the effect size for both BP variables increased by about 0·1 mmHg.» (Siervo et al., 2014)
This reads as a route-(b) effect-modification signal, the same pattern the sodium literature shows for its own BP effect (hypertensive >> normotensive, Sodium Intake and Blood Pressure) — but treat it as artifact-prone, not confirmed. A higher baseline BP mechanically permits a larger absolute fall (floor/regression-to-the-mean), and a cross-trial meta-regression of effect-size-on-baseline is exactly the design that manufactures such a signal — the sibling sodium page makes the same caution (Huang treats the hypertensive/normotensive dichotomy as a weak, arbitrarily-defined modifier -> Sodium Intake and Blood Pressure). The decision use below is conservative regardless of whether the modification is real. The studied range is above-optimal-BP / stage-1 hypertension with BMI ~23-37, so DASH’s BP benefit is demonstrated in an elevated-risk population and should not be read as a fixed effect for an optimal-BP, lean person. (inferred from Siervo et al., 2014)
Surrogate scope — BP is shown; hard events are not, and the authors say so
The meta-analysis measures risk factors over weeks. Its own Discussion draws the surrogate boundary explicitly:
«the efficacy of the DASH diet in reducing the risk of complications, reoccurrence of major cardiovascular events, and mortality in patients with more severe heart conditions is currently not known.» (Siervo et al., 2014)
So the DASH -> hard-outcome step is carried, not by these trials, but by the general BP -> events transmission: a proven ~10% reduction in major CV events per 5 mmHg SBP, reaching even primary prevention -> Blood Pressure Lowering and Cardiovascular Events (BPLTTC). Applying that transmission to DASH’s -5.2 mmHg SBP would predict a ~10% relative CV-event reduction — but that is an inference across a different intervention (BPLTTC is pharmacological lowering), so it is a plausible direction, not measured evidence, and the absolute benefit still scales with baseline risk (Baseline Risk and the Relative-Absolute Split). The one dietary BP route that did reach hard outcomes in the corpus is a potassium-enriched salt substitute (SSaSS), not DASH.
Symmetric-standards flag on the source’s own conclusion. Siervo’s abstract ends “The DASH diet is an effective nutritional strategy to prevent CVD” — a hard-outcome claim drawn from surrogate deltas plus a modelled Framingham projection, with no event measured. Read as an over-reach of exactly the surrogate-to-outcome kind Surrogate Outcomes warns against; the graded finding this page keeps is DASH lowers BP and atherogenic lipids, not that it prevents CVD events. (inferred from Siervo et al., 2014)
Which component is doing the work? The MA cannot decompose — but it is NOT the sodium
DASH is a multi-component pattern: higher fruit/vegetable/low-fat-dairy/wholegrain, lower red meat, sweets, total and saturated fat.
«the DASH dietary pattern promotes a higher intake of protective nutrients such as K, Ca, Mg, fibre and vegetable proteins and, at the same time, a lower intake of refined carbohydrates and saturated fat.» (Siervo et al., 2014)
The BP effect «may be due to the combined effects of these molecules on multiple physiological mechanisms» (antioxidant capacity, natriuresis, endothelial function, sympathetic activity; the authors also flag a high inorganic-nitrate intake, ~1200 mg/d, feeding NO generation). No single component can be isolated as the cause from this MA — it pools whole-pattern-vs-control contrasts, so the exposure is the bundle. The nitrate component is now estimated head-on by the same group’s dedicated MA -> Dietary Nitrate and Blood Pressure (Siervo 2013: dietary nitrate alone lowers SBP ~4.4 mmHg), which bounds how much of DASH’s -5.2 mmHg could be nitrate — but is the same team’s refinement (type-F), not independent corroboration, so it does not license summing DASH and nitrate as separate additive levers (overlapping NO mechanism). (Siervo et al., 2013, inferred from 2014) This is the pattern-as-exposure face of Is the Food Category Doing Any Work: the estimate describes the pattern, and attributing it to any one nutrient is beyond what the design identifies. (Siervo et al., 2014)
The one component the MA can partly rule OUT is sodium — partly, because a null is weak. Siervo’s meta-regression found the between-arm difference in dietary sodium did not predict the BP change; a non-significant meta-regression reflects limited power and modest between-trial Na variation as much as a true non-role (the same caveat the sodium page attaches to WHO’s null by-intake test), so this bounds sodium’s contribution to DASH’s effect rather than excluding it:
«Differences in dietary Na intake between the DASH and control intervention groups were not associated with changes in systolic and diastolic BP as well as with glucose and lipid concentrations». (Siervo et al., 2014)
Parameter table (op-weave 2a) — is DASH’s BP effect the same quantity as the sodium-reduction BP effect?
| Parameter | Siervo DASH 2015 | Sodium-reduction pages | Same quantity? |
|---|---|---|---|
| Exposure | whole DASH pattern vs control diet | sodium reduction vs usual sodium | NO — a multi-component pattern vs a single component |
| Pooled SBP effect | -5.2 mmHg (-7.0, -3.4), 20 RCTs | He -4.18 / WHO -3.39 mmHg (Sodium Intake and Blood Pressure) | NO — different exposure and comparator |
| Role of sodium in the effect | between-arm Na difference not associated with BP change (SBP P=0.67, DBP P=0.81) | sodium is the exposure | NO — DASH’s effect is not the sodium contrast |
Two consequences, kept distinct.
- Do not attribute DASH’s BP effect to its sodium content, and do not sum -5.2 (DASH) with -4.18 (sodium reduction) as if independent additive levers — they are overlapping-mechanism, not two clean additive channels, and Siervo shows the incidental Na differences between DASH and control arms are not what moved BP here.
- But DASH and salt restriction DO stack when both are deliberately applied. Siervo notes «feeding trials have demonstrated the additive effects of salt restriction on the efficacy of the DASH dietary pattern in reducing BP» (the DASH-Sodium factorial design). So adding a sodium cut on top of DASH buys further BP reduction — a complementary lever — even though DASH’s own vs-control effect is not driven by sodium. (Siervo et al., 2014)
(inferred from Siervo et al., 2014)
Limits
- Surrogate-only, 2-24 weeks. No hard endpoint; the CVD-prevention claim is a modelled projection.
- High heterogeneity on the primary outcome (SBP I2=76%), and some publication bias for TAG (Egger P=0.01).
- Almost entirely US / non-European trials — the authors flag limited evidence on applicability and acceptability outside the USA. Transportability of the magnitude is untested.
- Single gold-tier MA, no independent second pooling held —
confidence: medium. A DASH-Sodium or DASH-hard-outcome source would move this; the DASH -> events question stays open (type-G gap), answerable only via the BP-transmission cross-link, not directly.
(inferred from Siervo et al., 2014)
Decision relevance
- DASH is an evidenced BP-lowering pattern (-5.2/-2.6 mmHg vs control) with a modest LDL/total- cholesterol co-benefit and no glucose/HDL/TAG effect — a real surrogate move, larger in higher-BP / higher-BMI people.
- Its value on hard outcomes rides on the BP -> events chain, not on DASH trials — credit it the way you credit any lifestyle BP reduction, and weigh the absolute benefit by the person’s baseline CV risk, not by the mmHg alone.
- Do not double-count DASH with sodium reduction; treat them as complementary (stackable) levers, not additive-independent ones.
- The choice between named programmes barely matters for weight or BP (Named Diet Programs Compared, where between-diet differences are trivial) — but that is a between-diet statement; DASH-vs-usual-diet still buys a real BP reduction, and DASH is the pattern designed for and specifically pooled on BP here.